DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/krqb86/rankl_signaling) has announced the addition of the "RANKL Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.
Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily. It binds to Receptor activator of NF-kB (RANK) and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C (PKC), Ca2+/Calcineurin/nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). The RANKL-RANK signaling system is negatively regulated by a decoy receptor known as Osteoprotegerin.
There are today 192 companies plus partners developing 276 RANKL pathway targeting drugs in 1051 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 139 drugs.
Rankl Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 136 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 134 out of the 136 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 34 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
- Includes more than 192 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Drug name & Synonyms
- Lists commercial, generic and code names for drugs.
- This Drug Pipeline Update contains 276 RANKL pathway targeting drugs in development, which have a total of 1051 developmental projects in cancer. In addition there are suspended and ceased drugs.
- Included RANKL pathway targeting drugs are also in development for 160 other indications, where of 107 are different cancer indications.
Pipeline Breakdown According to Number of Drugs
- Marketed # 22
- Registered # 1
- Pre-registration # 4
- Phase III # 29
- Phase II # 95
- Phase I # 128
- Preclinical # 135
- No Data # 2
- Suspended # 1
- Ceased # 139
For more information visit http://www.researchandmarkets.com/research/krqb86/rankl_signaling